Vetter announces new V-OVS® syringe closure system

The new V-OVS® syringe closure system from Vetter combines valuable practical experience and feedback from numerous customers with the goal of setting a new standard for the functionality of injection systems. © Vetter Pharma International GmbH

– Improved performance through advanced design, handling, and opening mechanism
– New system aims to set a new standard for the functionality of injection systems
– Closure system builds on successful customer applications

The globally operating pharmaceutical service provider Vetter has announced the development and upcoming market launch of the new version of its patented V-OVS® syringe closure system.

V-OVS® next is the further development of a patented system that has proven successful worldwide for differentiating various sterile injectables over many years. The new version combines a series of technical advancements, developed in response to changing market needs and feedback from numerous customers who use V-OVS® for their innovative medications. Like the current system, the design of V-OVS® next is optimized to ensure the integrity of the injectable product. Easier handling features and an even more intuitive opening mechanism enable customers offering active ingredients in glass syringe bodies to achieve improved integration of Luer-Lock features.

Improvements for broader application

"We are convinced that V-OVS® next, with its patented syringe closure technology, will offer a new level of user-friendliness for Luer-Lock applications," says Tobias Nemeth, Head of Primary Packaging Development at Vetter. "It builds on our decades-long market presence with this industry-leading system and offers customers a wider range of injectable products additional options." In addition to improved handling, the size of the closure has also been reduced to better adapt to smaller syringe sizes. New improved grip surfaces provide greater control during opening. With a sturdy new locking mechanism, the closure remains reliably in the correct position even in very demanding applications.

The V-OVS® next is currently in development and is scheduled to launch in 2027. Vetter is currently finalizing the product design and preparing for the market launch of the new system. Recently, the pharmaceutical service provider conducted a successful human factors study with a representative group of clinical users. The study received consistently positive feedback, which will directly contribute to finalizing the design phase of the new closure system.

Following the market launch of the new V-OVS® next, Vetter will continue to offer its established V-VOS® model and, with this portfolio expansion, provide its customers with even more options for their syringe-based products.